Similar articles

• Duration of isoniazid preventive therapy in HIV-infected patients.

  Dutt N. Dutt N. Lancet. 2011 Oct 1;378(9798):1216; author reply 1216-7. doi: 10.1016/S0140-6736(11)61532-8. Lancet. 2011. PMID: 21962553 No abstract available.
• High completion of isoniazid preventive therapy among HIV-infected children and adults in Kinshasa, Democratic Republic of Congo.

  Yotebieng M, Edmonds A, Lelo P, Wenzi LK, Ndjibu PT, Lusiama J, Kabuayi JP, Behets F. Yotebieng M, et al. AIDS. 2015 Sep 24;29(15):2055-7. doi: 10.1097/QAD.0000000000000791. AIDS. 2015. PMID: 26352882 Free PMC article.
• Isoniazid-induced subacute cutaneous lupus erythematosus in an HIV-positive woman: a rare side effect to be aware of with the current expansion of isoniazid preventive therapy.

  Luwanda LB, Gamell A. Luwanda LB, et al. Pan Afr Med J. 2018 Apr 6;29:200. doi: 10.11604/pamj.2018.29.200.12081. eCollection 2018. Pan Afr Med J. 2018. PMID: 30061978 Free PMC article. No abstract available.
• Preventive therapy for tuberculosis in HIV infected individuals.

  Padmapriyadarsini C, Swaminathan S. Padmapriyadarsini C, et al. Indian J Med Res. 2005 Apr;121(4):415-23. Indian J Med Res. 2005. PMID: 15817954 Review.
• Isoniazid preventive therapy in HIV-infected and -uninfected children (0 - 14 years).

  Schaaf HS, Cotton MF, Boon GP, Jeena PM. Schaaf HS, et al. S Afr Med J. 2013 Sep 4;103(10):714-5. doi: 10.7196/samj.7189. S Afr Med J. 2013. PMID: 24079619 Review.